Granules India Limited

GRANULES

INE101D01020

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:00:52 2026-07-17 am EDT			5-day change	1st Jan Change
880.10 ^INR	-2.55%		-1.06%	+47.04%

Jul. 06	Granules India Gets Sole First-to-File Status for Sodium Oxybate Extended-Release for Oral Suspension	MT
Jul. 05	Granules India Limited Secures Sole First-To-File ANDA Status For Sodium Oxybate Extended-Release For Oral Suspension	CI

Granules India Limited Designates Mr. Harsha Chigurupati as Senior Management Personnel, Effective April 30, 2026

Published on 04/29/2026 at 03:18 am EDT

S&P Capital IQ

Add MarketScreener to your sources

GRANULES INDIA LIMITED

-2.55%

Granules India Limited at the Board meeting held on April 29, 2026 has designated Mr. Harsha Chigurupati, Executive Director of the Company as a Senior Management Personnel of the Company with effect from April 30, 2026 responsible for Transformation & Information Technology, Project Management and Leadership Hiring.

Add MarketScreener to your sources

Latest news about Granules India Limited

Jul. 06	Granules India Gets Sole First-to-File Status for Sodium Oxybate Extended-Release for Oral Suspension	MT
Jul. 05	Granules India Limited Secures Sole First-To-File ANDA Status For Sodium Oxybate Extended-Release For Oral Suspension	CI
Jun. 12	Sushil Finance Starts Granules India at Buy with INR963 Price Target	MT
May. 01	Choice Equity Broking Downgrades Granules India to Add from Buy; Price Target is INR835	MT
Apr. 29	Granules India Limited, Q4 2026 Earnings Call, Apr 29, 2026
Apr. 29	Granules India Q4 consol profit 2.02 billion rupees	RE
Apr. 29	Granules India Limited Recommends Final Dividend for the Financial Year 2025-2026	CI
Apr. 29	Granules India's fourth-quarter profit jumps on strong demand	RE
Apr. 29	Granules India Limited Designates Mr. Harsha Chigurupati as Senior Management Personnel, Effective April 30, 2026	CI
Apr. 29	Granules India Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026	CI
Apr. 09	Indian drugmaker Granules to tighten oversight after US FDA warning, exec says	RE
Mar. 31	Granules receives VAI classification after US FDA inspection	RE
Mar. 05	Granules India Arm Gets "No Action Indicated" Status from US FDA for Viginia Unit; Shares Up 3%	MT
Mar. 05	Granules says packaging facility in US gets FDA EIR with No Action Indicated status	RE
Feb. 24	Granules India: Analysts Bet on Continued Upside

Chart Granules India Limited

Duration

Period

GRANULES: Dynamic Chart

Company Profile

Granules India Limited is an India-based pharmaceutical manufacturing company. The Company operates through its pharmaceutical products segment. Its geographical segments include within India and outside India. The Company has a presence across the pharmaceutical manufacturing value chain, including active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediaries (PFIs) and finished dosages (FDs). It produces and supplies Paracetamol, Metformin, Guaifenesin, and Methocarbamol APIs. It has over 10 manufacturing facilities, approximately eight of which are located in India and two in the United States. The Company sells its products in global markets, including the United States of America, Canada, Latin America, Europe, Asia Pacific, and India. Its subsidiaries include Granules USA Inc and Granules Europe Limited. It also owns Senn Chemicals AG, a contract development and manufacturing organization (CDMO) specializing in peptide development and manufacturing.

Employees

4,306

Sector

Pharmaceuticals

Calendar

Earnings release - Q1 2027

More about the company